Dyve Biosciences Announces Phase 2 TARGETS Study of DYV702 for Pain Associated with Acute Gout Flares Showcased in Podium Presentation at 2022 EULAR Congress
June 01, 2022 11:52 ET
|
Dyve Biosciences
CAMARILLO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of...
Dyve Biosciences to Participate in the BIO International Convention
June 01, 2022 08:00 ET
|
Dyve Biosciences
CAMARILLO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of...
Dyve Biosciences to Present at the UBS Global Healthcare Conference
May 04, 2022 08:30 ET
|
Dyve Biosciences
CAMARILLO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of...
Dyve Biosciences to Present at the 34th Annual Roth Conference
March 09, 2022 08:00 ET
|
Dyve Biosciences
CAMARILLO, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline...
Dyve Biosciences Announces the Appointment of Nicholas A. Saccomano, Ph.D., to its Scientific Advisory Board
March 01, 2022 07:00 ET
|
Dyve Biosciences
- Former Array BioPharma and Pfizer Executive Joins Dyve Biosciences - CAMARILLO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company...
Dyve Biosciences to Present at the Biocom California Global Life Science Partnering Conference
February 22, 2022 08:00 ET
|
Dyve Biosciences
CAMARILLO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of...
Dyve Biosciences to Present at the 32nd Annual Oppenheimer Healthcare Conference
February 16, 2022 08:00 ET
|
Dyve Biosciences
CAMARILLO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of...
Dyve Biosciences Announces Research and Development Collaboration with Moffitt Cancer Center
February 03, 2022 08:00 ET
|
Dyve Biosciences
CAMARILLO, Calif. and TAMPA, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a...
Dyve Biosciences Hosting Key Opinion Leader Webinar on Gout and DYV702
November 15, 2021 08:00 ET
|
Dyve Biosciences
Two key opinion leaders will discuss gout treatment landscape and perspectives on Phase 2 TARGETS study of DYV702 for the treatment of pain associated with acute gout flares Webinar to be...
Dyve Biosciences Appoints Camilla V. Simpson to Board of Directors
February 01, 2021 08:00 ET
|
Dyve Biosciences
THOUSAND OAKS, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical stage biotechnology company, today announced that Camilla V. Simpson has joined Dyve’s Board of...